Journal of Clinical Endocrinology & Metabolism, Vol 70, 859-864, Copyright © 1990 by Endocrine Society

ARTICLES

Prevalence of alpha-subunit hypersecretion in patients with pituitary tumors: clinically nonfunctioning and somatotroph adenomas

DS Oppenheim, AR Kana, JS Sangha and A Klibanski
Neuroendocrine Unit, Massachusetts General Hospital, Boston 02114.

Hypersecretion of the pituitary glycoprotein hormone alpha-subunit has been reported in pituitary adenomas, particularly in clinically nonfunctioning tumors and somatotroph adenomas. However, the prevalence of such hypersecretion has not been precisely defined. Using both a new highly sensitive and specific monoclonal antibody assay and a polyclonal antibody assay, serum levels of free alpha-subunit were compared in 63 unselected patients with these tumors, 19 patients with acromegaly, and 95 normal controls. In all patients the monoclonal assay detected a significantly greater number of subjects with elevated alpha-subunit levels than did the polyclonal assay (21 vs. 14; P less than 0.01). Fourteen of the 63 patients with clinically nonfunctioning tumors (22%) had elevated serum alpha-subunit levels in the monoclonal assay vs. 11 (17%) in the polyclonal assay. Among the 19 patients with acromegaly, the prevalence was 7 (37%) and 3 (16%) using the monoclonal and polyclonal assays, respectively. Twenty-eight (44%) of the patients with clinically nonfunctioning pituitary adenomas were female. Eleven (39%) of the women were under 45 yr old, as were 10 (29%) of the men. We conclude that the prevalence of free alpha-subunit hypersecretion in patients with clinically nonfunctioning and somatotroph adenomas may be higher than previously recognized, and that a sensitive and specific monoclonal antibody free alpha-subunit assay may provide a useful tumor marker in these patients. The prevalence of clinically nonfunctioning pituitary tumors among younger men and women may also have been previously under-estimated.

This article has been cited by other articles:

				R. A. Abbud, I. Takumi, E. M Barker, S.-G. Ren, D.-Y. Chen, K. Wawrowsky, and S. Melmed Early Multipotential Pituitary Focal Hyperplasia in the {alpha}-Subunit of Glycoprotein Hormone-Driven Pituitary Tumor-Transforming Gene Transgenic Mice Mol. Endocrinol., May 1, 2005; 19(5): 1383 - 1391. [Abstract] [Full Text] [PDF]

				C. J. McCabe, N. J. Gittoes, M. C. Sheppard, and J. A. Franklyn Thyroid Receptor {alpha}1 and {alpha}2 Mutations in Nonfunctioning Pituitary Tumors J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 649 - 653. [Abstract] [Full Text]

				E. J. Lee, L. M. Anderson, B. Thimmapaya, and J. L. Jameson Targeted Expression of Toxic Genes Directed by Pituitary Hormone Promoters: A Potential Strategy for Adenovirus-Mediated Gene Therapy of Pituitary Tumors J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 786 - 794. [Abstract] [Full Text]

				E. Baudin, J.-M. Bidart, P. Rougier, V. Lazar, P. Ruffié, J. Ropers, M. Ducreux, F. Troalen, J.-C. Sabourin, E. Comoy, et al. Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 69 - 75. [Abstract] [Full Text]

				J. T. King Jr., A. C. Justice, and D. C. Aron Management of Incidental Pituitary Microadenomas: A Cost-Effectiveness Analysis J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3625 - 3632. [Abstract] [Full Text] [PDF]

				N. J. L. Gittoes, C. J. McCabe, J. Verhaeg, M. C. Sheppard, and J. A. Franklyn Thyroid Hormone and Estrogen Receptor Expression in Normal Pituitary and Nonfunctioning Tumors of the Anterior Pituitary J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1960 - 1967. [Abstract] [Full Text] [PDF]

				P. Chanson, J. Pantel, J. Young, B. Couzinet, J.-M. Bidart, and G. Schaison Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1397 - 1402. [Abstract] [Full Text] [PDF]